ARCHIVES

“Wild West” of Molecular Testing?: Caris Engaged in Aggressive Marketing, Improper Medicare Billing, Lawsuit Alleges

This article is from The Cancer Letter archive.

Vol. 40 No. 32 | August 8, 2014

Download PDF Visit The Full Archive

Related Articles

AVEO’s Tivozanib Sunk by Fundamental Flaw: Higher Overall Survival in the Control Arm

May 8, 2013

FDA says new tools needed to speed therapeutics development.

March 26, 2004

NCI Will Encourage More Activity In Environment Carcinogenesis

June 21, 1974

Final stats On FY92 Budget; Success Rate Was 35 Percent

December 4, 1992

Suspect Chemical Include Castor Oil, Witchhazel; Details On 38 Picked For Long Term Tests

August 5, 1977

Two Phase III Ramucirumab Trials Both Deliver Improved Overall and Progression-Free Survival

October 25, 2013